Pay-for-Delay: Antitrust Class Action Claims Takeda Paid to Keep Generic IBS Drug Off the Market
July 1, 2021 A class action alleges Takeda and Par violated antitrust law when the two struck an agreement to keep the latter’s generic version of Amitiza off the market for up to six years.